Insider · CIK 0002083482
Dan Weng
Files at GYRE (GYRE THERAPEUTICS, INC.). First filing -, latest -.
Dan Weng files SEC Form 4 as director at GYRE (GYRE THERAPEUTICS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Dan Weng has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | GYRE GYRE THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jun 30, 2026 |
| Aug 18, 2025 | GYRE GYRE THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +52,000 | $0.00 | $0 | 52,000 | Aug 26, 2025 |
Questions about Dan Weng
Answered from the filings on this page, as of the latest one.
Is Dan Weng buying or selling?
Dan Weng has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Dan Weng's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Dan Weng has 0.
Where does Dan Weng file Form 4?
Dan Weng has filed Form 4 at GYRE (GYRE THERAPEUTICS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.